enGene Revenue and Competitors

Claim your profile

St-Laurent,

Location

$33.3M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • enGene's estimated annual revenue is currently $10.4M per year.(i)
  • enGene's estimated revenue per employee is $155,000
  • enGene's total funding is $33.3M.

Employee Data

  • enGene has 67 Employees.(i)
  • enGene grew their employee count by -12% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$156.1M514-6%$145MN/A
#2
$14M90-37%$150MN/A
#3
$5.4M35-8%N/AN/A
#4
$4.8M31-22%N/AN/A
#5
$5.3M34-35%N/AN/A
#6
$53.9M348-35%$75.1MN/A
#7
$7.9M51-11%N/AN/A
#8
$14.7M95-4%N/AN/A
#9
$7910M158445%$204.3MN/A
#10
$13.2M106-49%$263.3MN/A

enGene Inc. is a biotechnology company developing a proprietary non-viral gene therapy platform for localized delivery of nucleic acid payloads to mucosal tissues. The dually derived chitosan (DDX) platform has a high-degree of payload flexibility including DNA and various forms of RNA (siRNA, shRNA, lncRNA etc.) with broad tissue and disease applications. In addition to developing EG-70 for BCG-unresponsive NMIBC, enGene enGene is developing unique genetic medicines for respiratory indications. The company is also evolving its technology to enable applications in several mucosal tissues such as the nasal and genital mucosa as well as the gastrointestinal tract among others. enGene is supported financially by top-tier institutional investors including Forbion Capital Partners, Fonds de Solidarité FTQ, Pharmstandard International S.A., Lumira Capital and Johnson & Johnson Development Corporation.

keywords:N/A

$33.3M

Total Funding

67

Number of Employees

$10.4M

Revenue (est)

-12%

Employee Growth %

N/A

Valuation

N/A

Accelerator

enGene News

2022-03-22 - enGene Appoints James C. Sullivan, PhD as Chief Scientific ...

About enGene Inc. enGene Inc. is a clinical-stage biotechnology company developing non-viral gene therapies based on localized delivery of...

2015-01-26 - enGene raises CAD 13.5 million (US$11.5M) to develop intestinal gene delivery platform

enGene Inc., a Montréal-based biotechnology enterprise developing an innovative platform technology for delivering genes to cells lining the gastrointestinal tract, announced today the closing of a $13.5 million Series B investment round led by Forbion Capital Partners, with participation of new ...

2013-08-02 - enGene Raises $13.25M Financing

enGene Inc., a Montreal, Quebec, Canada-based pre-clinical stage biopharmaceutical company developing a platform technology for the delivery of nucleotides (DNA or RNA) to the gut, has held an initial closing of a $13.25m financing. The round was led by Lumira Capital (via its Merck Lumira Bios ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$8.7M67-40%N/A
#2
$15.4M703%N/A
#3
$25.3M774%N/A
#4
N/A95-7%N/A
#5
$14.4M992%N/A